JHL opens biologics manufacturing site in China

JHL Biotech Inc. (TPex-E:6540) said it opened a biomanufacturing facility in Wuhan, giving it the largest single-use cell culture capacity in Asia.

The new manufacturing facility is designed to produce biosimilars and mAbs for clinical trials and commercial supply, as well as contract manufacturing. JHL completed the facility's construction in 18 months under a partnership with the GE Healthcare unit of General Electric Co. (NYSE:GE), using GE's KUBio prefabricated module system. ...